Stockscreener 앱 받기
86.17
2.05%
-1.80
시간 외 거래:
85.00
-1.17
-1.36%
전일 마감가:
$87.97
열려 있는:
$88.2
하루 거래량:
364.06K
Relative Volume:
0.45
시가총액:
$5.93B
수익:
$217.17M
순이익/손실:
$-202.68M
주가수익비율:
-37.42
EPS:
-2.3028
순현금흐름:
$-156.63M
1주 성능:
-5.08%
1개월 성능:
-12.08%
6개월 성능:
-2.20%
1년 성능:
-22.50%
1일 변동 폭
$85.91
$88.62
1주일 범위
$85.38
$91.42
52주 변동 폭
$74.50
$122.20
Rhythm Pharmaceuticals Inc Stock (RYTM) Company Profile
명칭
Rhythm Pharmaceuticals Inc
전화
857-264-4280
주소
222 BERKELEY STREET, BOSTON, MA
Compare RYTM vs VRTX, MRNA, REGN, ARGX, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
RYTM
Rhythm Pharmaceuticals Inc
|
86.17 | 5.93B | 217.17M | -202.68M | -156.63M | -2.3028 |
VRTX
Vertex Pharmaceuticals Inc
|
499.74 | 126.66B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
218.01 | 87.04B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
790.74 | 81.41B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
819.14 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
369.06 | 41.75B | 5.76B | 514.49M | 1.10B | 4.4813 |
Rhythm Pharmaceuticals Inc Stock (RYTM) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-09-17 | 개시 | Wolfe Research | Outperform |
| 2026-09-14 | 재개 | Leerink Partners | Outperform |
| 2026-08-28 | 개시 | Deutsche Bank | Hold |
| 2026-07-27 | 개시 | JP Morgan | Overweight |
| 2026-02-19 | 개시 | RBC Capital Mkts | Outperform |
| 2025-11-25 | 개시 | Citigroup | Buy |
| 2025-11-05 | 다운그레이드 | Oppenheimer | Outperform → Perform |
| 2025-07-10 | 개시 | Goldman | Buy |
| 2025-07-07 | 개시 | Leerink Partners | Outperform |
| 2025-04-07 | 업그레이드 | BofA Securities | Neutral → Buy |
| 2025-03-05 | 재개 | Stifel | Buy |
| 2025-01-02 | 개시 | Jefferies | Buy |
| 2024-12-20 | 개시 | Oppenheimer | Outperform |
| 2024-10-21 | 개시 | Guggenheim | Buy |
| 2024-09-18 | 개시 | H.C. Wainwright | Buy |
| 2024-09-17 | 개시 | JMP Securities | Mkt Outperform |
| 2024-05-08 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2023-12-19 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2023-08-01 | 업그레이드 | BofA Securities | Neutral → Buy |
| 2023-01-18 | 재개 | Canaccord Genuity | Buy |
| 2022-08-08 | 업그레이드 | Goldman | Neutral → Buy |
| 2022-08-05 | 업그레이드 | BofA Securities | Underperform → Neutral |
| 2022-06-17 | 재확인 | Needham | Buy |
| 2022-03-02 | 재개 | Stifel | Buy |
| 2022-02-17 | 업그레이드 | Ladenburg Thalmann | Neutral → Buy |
| 2021-12-08 | 개시 | Wells Fargo | Overweight |
| 2021-11-19 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2021-09-14 | 재개 | Goldman | Neutral |
| 2021-08-04 | 다운그레이드 | BofA Securities | Neutral → Underperform |
| 2021-08-04 | 다운그레이드 | Ladenburg Thalmann | Buy → Neutral |
| 2020-11-30 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2020-01-08 | 개시 | Goldman | Sell |
| 2019-07-12 | 업그레이드 | Stifel | Hold → Buy |
| 2019-07-08 | 개시 | Canaccord Genuity | Buy |
| 2019-03-13 | 개시 | Ladenburg Thalmann | Buy |
| 2018-09-07 | 재개 | Morgan Stanley | Overweight |
| 2018-06-25 | 재확인 | Needham | Buy |
| 2018-06-15 | 재확인 | Needham | Buy |
| 2017-10-30 | 개시 | BofA/Merrill | Buy |
| 2017-10-30 | 개시 | Needham | Buy |
모두보기
Rhythm Pharmaceuticals Inc 주식(RYTM)의 최신 뉴스
Rhythm Pharmaceuticals Announces Commercial Launch of IMCIVREE® (setmelanotide) in Japan for Patients with Acquired Hypothalamic Obesity - GlobeNewswire Inc.
Rhythm Pharmaceuticals (RYTM) Upgraded to Buy: Here's What You Should Know - Zacks Investment Research
Rhythm Pharmaceuticals Inc (NASDAQ: RYTM) Share Price, RYTM Stock News, RYTM Share Price & Updates - kalkine.ca
Rhythm Pharmaceuticals, Inc. (RYTM) Stock Price, News, Quote & History - Yahoo! Finance Canada
Rhythm Pops on Health Canada Nod - baystreet.ca
Rhythm Pops on Health Canada Nod - Baystreet.ca
RHYTHM Pharmaceuticals CEO David P. Meeker Executes Option Exercise and Sells 50,000 Shares - Kalkine Media
Rhythm Pharmaceuticals Insider Sold Shares Worth $5,133,442, According to a Recent SEC Filing - finance.yahoo.com
Rhythm Pharmaceuticals (RYTM) CEO sells 50,000 shares under preset plan - Stock Titan
Insider lines up multimillion-dollar stock sale at Rhythm Pharmaceuticals (NASDAQ: RYTM) - Stock Titan
Rhythm Pharmaceuticals president & CEO Meeker sells $5.13m stock - Investing.com
Avoiding Lag: Real-Time Signals in (RYTM) Movement - Stock Traders Daily
Obesity Market to Witness Strong Growth and Significant Market Expansion by 2036 – DelveInsight | Rhythm Pharma, Boehringer Ingelheim, D&D Pharmatech, ProQR Therapeutics, Nano Precision Medical - Barchart.com
Exploring 3 High Growth Tech Stocks In The US Market - simplywall.st
Exploring 3 High Growth Tech Stocks In The US Market - simplywall.st
Rhythm Pharmaceuticals Announces New Data Presentations at the European Society for Paediatric Endocrinology Meeting - manilatimes.net
French children showed lower body-size scores on a rare-obesity drug - Stock Titan
Rhythm Pharmaceuticals at Wells Fargo conference: ho launch gains traction By Investing.com - Investing.com Canada
Rhythm Pharmaceuticals at Wells Fargo conference: ho launch gains traction By Investing.com - Investing.com UK
Rhythm Pharmaceuticals, Inc. (RYTM) Stock Analysis: A 36.45% Potential Upside in the Biotech Arena - DirectorsTalk Interviews
An AI drug specialist zeroes in on rare forms of obesity - BioPharma Dive
Here’s How Much You Would Have Made Owning Rhythm Pharmaceuticals Stock In The Last 5 Years - Benzinga
Rhythm Pharmaceuticals stock edges lower after insider sale but stays backed by strong Q2 growth - AD HOC NEWS
How Rhythm Pharmaceuticals Inc. (RYTM) Affects Rotational Strategy Timing - Stock Traders Daily
Rhythm Pharmaceuticals(RYTM.US) Officer Sells US$6.62 Million in Common Stock - Moomoo
Rhythm Pharmaceuticals (RYTM) CFO sells 62,774 shares in planned trade - Stock Titan
Rhythm (NASDAQ: RYTM) officer files Rule 144 stock sale notice - Stock Titan
Here's How Much $100 Invested In Rhythm Pharmaceuticals 5 Years Ago Would Be Worth Today - Benzinga
Rhythm Pharmaceuticals (RYTM): Investor Outlook on a 30.81% Potential Upside in Biotechnology - DirectorsTalk Interviews
Rhythm Pharmaceuticals Inc. (RYTM) Financials – Balance Sheet, Profit & Loss, Cash Flow - valueresearchonline.com
RHYTHM PHARMACEUTICALS, INC. : DEUTSCHE BANK INITIATES COVERAGE WITH HOLD RATING AND TARGET PRICE $120 - webull.com
Deutsche Bank Initiates Rhythm Pharmaceuticals(RYTM.US) With Hold Rating, Announces Target Price $120 - Moomoo
ZLAB Stock Price, Quote & News - Syfe
Parabilis Medicines, Inc. (PBLS) Stock Price & News - Syfe
Deutsche Bank Initiates Rhythm Pharmaceuticals(RYTM.US) With Hold Rating, Announces Target Price $120 - Moomoo
Deutsche Bank Initiates Rhythm Pharmaceuticals at Hold With $120 Price Target - marketscreener.com
Rhythm Pharmaceuticals (RYTM) Could Be 15% Undervalued As Japan Approval Lifts Its Story - sahmcapital.com
Rhythm Pharmaceuticals Gains Japan Approval For IMCIVREE In Hypothalamic Obesity - DirectorsTalk Interviews
Rhythm Pharmaceuticals (RYTM) Stock Looks Overvalued Despite Its 7x Five Year Run - Yahoo Finance
Rhythm Pharmaceuticals Announces MHLW Approval of IMCIVREE® (setmelanotide) for Patients with Acquired Hypothalamic Obesity (HO) in Japan - The Manila Times
Rhythm Pharmaceuticals, Inc. (RYTM) Stock Analysis: Biotechnology Innovator Seeks 28.67% Upside with Breakthrough Therapies - DirectorsTalk Interviews
Japan Grants Marketing Authorization to First Therapy for Rare Obesity Affecting 5,000–8,000 People - Stock Titan
Eli Lilly and Novo Nordisk Can't Treat This Form of Obesity. Billionaire Stanley Druckenmiller Is Betting Rhythm Pharmaceuticals Can - Yahoo Finance
Blue Owl Capital Holdings LP Invests $6.82 Million in Rhythm Pharmaceuticals, Inc. $RYTM - MarketBeat
TD Cowen Names Rhythm Pharmaceuticals Its Top Pick Following Robust Q2 Results - StockInvest.us
Rhythm Pharmaceuticals (RYTM) grants CMO 50K options expiring 2036 - Stock Titan
Rhythm (RYTM) CMO reports no company stock holdings - Stock Titan
Rhythm Pharmaceuticals (RYTM) Stock Looks Pricey Following Strong IMCIVREE News - Sahm
Rhythm Pharmaceuticals Announces Appointment of Manher (AJ) Joshi as Chief Medical Officer - Sahm
Rhythm Pharmaceuticals: Building A Defensive MC4R Franchise (NASDAQ:RYTM) - Seeking Alpha
Rhythm Pharmaceuticals Inc (RYTM) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Rhythm Pharmaceuticals Inc 주식 (RYTM) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| David Meeker | Director |
Sep 14 '26 |
Proposed Sale |
104.71 |
50,000 |
5,235,500 |
0 |
| Meeker David P | President and CEO |
Sep 14 '26 |
Sale |
102.67 |
50,000 |
5,133,442 |
239,258 |
| Smith Hunter C | Chief Financial Officer |
Aug 31 '26 |
Option Exercise |
25.79 |
57,187 |
1,474,853 |
176,798 |
| HUNTER SMITH | Officer |
Aug 31 '26 |
Proposed Sale |
107.17 |
62,774 |
6,727,490 |
0 |
| Smith Hunter C | Chief Financial Officer |
Aug 31 '26 |
Sale |
105.46 |
62,774 |
6,619,913 |
114,024 |
| Shulman Joseph | Chief Technical Officer |
Aug 13 '26 |
Sale |
119.75 |
5,079 |
608,210 |
15,915 |
| Garfield Alastair | Chief Scientific Officer |
Aug 13 '26 |
Sale |
117.57 |
7,763 |
912,703 |
2,295 |
| Shulman Joseph | Chief Technical Officer |
Aug 13 '26 |
Option Exercise |
6.80 |
2,024 |
13,763 |
20,994 |
| JOSEPH J SHULMAN | Officer |
Aug 13 '26 |
Proposed Sale |
117.60 |
5,079 |
597,290 |
0 |
| Jennifer Kayden Lee | Officer |
Aug 13 '26 |
Proposed Sale |
117.60 |
75,834 |
8,918,078 |
0 |
0.99%
자본화:
|
볼륨(24시간):